×
About 13,918 results

ALLMedicine™ Neuroblastoma Center

Research & Reviews  4,904 results

Alzheimer's disease is associated with disruption in thiamin transport physiology: A po...
https://doi.org/10.1016/j.nbd.2022.105799
Neurobiology of Disease; Ramamoorthy K, Yoshimura R et. al.

Jun 25th, 2022 - Alzheimer's disease (AD) is a neurodegenerative disease characterized by Amyloid-β peptide (Aβ) containing plaques and cognitive deficits. The pathophysiology of AD also involves neuroinflammation. Vitamin B1 (thiamin) is indispensable for normal ...

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
https://clinicaltrials.gov/ct2/show/NCT03206060

Jun 24th, 2022 - Background: Pheochromocytomas/paragangliomas (PHEOs/PGLs) are rare tumors arising from neural crest tissue that can develop in sympathetic and parasympathetic paraganglia throughout the body. Those arising in the adrenal gland are called PHEOs whi...

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
https://clinicaltrials.gov/ct2/show/NCT05012098

Jun 24th, 2022 - Background: Olfactory neuroblastoma (ONB, also known as esthesioneuroblastoma), is a rare malignant neoplasm of the nasal cavity. At diagnosis, ONB is often locally advanced. It tends to invade locally and has high rates of regional spread to the ...

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
https://clinicaltrials.gov/ct2/show/NCT04086485

Jun 24th, 2022 - Background: Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and heterogeneous, but clinically important, group of neoplasms with unique tumor biology, natural history, and clinical management issues. While the tr...

see more →

Guidelines  1 results

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696761
British Journal of Cancer; Beiske K, Burchill SA et. al.

Apr 30th, 2009 - Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task...

see more →

Drugs  48 results see all →

Clinicaltrials.gov  431 results

Validating Pain Scales in Children and Young Adults
https://clinicaltrials.gov/ct2/show/NCT01639950

Jun 24th, 2022 - Background: Pain is a common symptom among children with a variety of medical illnesses. Currently, a number of rating scales are used to assess pain interference and pain severity in adults. However, relatively few measures assessing these variab...

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT01804634

Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (HSCT) may be associated with a clinically significant "graft-versus-tumor" (GVT) effect, even against disease that is unresponsive to chemotherapy and radiation therapy. Graft-vs.-tumor (GVT) eff...

A Natural History Study of Children and Adults With Olfactory Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT04755205

Jun 24th, 2022 - Background: Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 ...

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
https://clinicaltrials.gov/ct2/show/NCT04086485

Jun 24th, 2022 - Background: Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and heterogeneous, but clinically important, group of neoplasms with unique tumor biology, natural history, and clinical management issues. While the tr...

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03027388

Jun 24th, 2022 - Background: Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet ne...

see more →

News  177 results

FDA Accepts NDA Resubmission for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/fda-accepts-nda-resubmission-for-pedmark-in-prevention-of-platinum-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The FDA has accepted for filing the new drug application (NDA) resubmission for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have l...

NDA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/nda-resubmitted-to-fda-for-pedmark-in-prevention-of-cisplatin-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The new drug application seeking the approval of a unique formulation of sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmeta...

Activating the Immune System Could be Key to Treating Pediatric Neuroblastoma
https://www.onclive.com/view/activating-the-immune-system-could-be-key-to-treating-pediatric-neuroblastoma

Mar 10th, 2022 - Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma. Wayne Furman, MD, hopes that the humanized anti-disialoganglioside (anti-GD2) monoclonal antibody hu14.18K322A provides a breakthrough for children wi...

Rare Cancers Report: Pediatric Neuroblastoma
https://www.onclive.com/view/rare-cancers-report-pediatric-neuroblastoma

Feb 3rd, 2022 - Welcome to OncLiveOn Air®! I’m your host today, Jessica Hergert. OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and p...

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatment
https://www.onclive.com/view/yale-cancer-center-researchers-show-receptor-structure-reveals-new-targets-for-cancer-treatment

Dec 10th, 2021 - A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule — its role in the body, which molecules inte...

see more →

Patient Education  6 results see all →